Science News Hubb
Advertisement
  • Home
  • Science News
  • Technology
  • Contact us
No Result
View All Result
  • Home
  • Science News
  • Technology
  • Contact us
No Result
View All Result
Science News Hubb
No Result
View All Result
Home Technology

Psilocybin Relieves Some Treatment-Resistant Depression Cases: Trial

admin by admin
November 4, 2022
in Technology



For years, some researchers have looked to psychedelic drugs, including psilocybin (the active ingredient in so-called magic mushrooms), as a potential treatment for some psychiatric conditions. The largest trial to date of psilocybin for depression, published today (November 3) in the New England Journal of Medicine, finds that a dose of synthetic psilocybin combined with counseling did alleviate symptoms for some patients. But for some participants who did respond, the effects wore off within 12 weeks of the treatment.

“It’s a big step forward for the field of psychedelic research and depression treatment,” Jimmy Potash, who oversees psychedelics research at Johns Hopkins but was not involved in the study, tells STAT. The durability of the response is “not as good as you’d like, but it’s still quite good,” he adds.

The Phase 2 clinical trial, funded in part by the mental health care startup Compass Pathways, which makes the synthetic psilocybin used in the study, included 233 patients for whom at least two depression medications had not worked. The participants were randomly assigned to receive psilocybin at one of three dosing levels: 25 mg, 10 mg, or 1 mg (used as a control). Volunteers in all three groups received counseling before and after the psilocybin use and were monitored during their experience with the drug.

Three weeks after treatment, all three groups saw a fall in their average score on a standard rating scale of depression indicators (indicating less severe cases) relative to their scores prior to treatment, according to the paper, with the largest improvement in the highest-dose group. STAT notes that 29 percent of those high-dose participants were in remission at the three-week mark, a number that dropped to 20 percent at 12 weeks, while 37 percent had their depression score halved by the three-week mark.

See “Decoding the Tripping Brain”

“Response rates in this group with treatment-resistant depression are usually between 10 and 20%,” Guy Goodwin, Compass’s chief medical officer, tells The Guardian. “We are seeing remission rates at three weeks of about 30% … that is a very satisfactory outcome.”

Ravi Das of the University College London Institute of Mental Health, who was not involved in the study, tells Reuters that the results are positive, but highlights a potential weakness in the clinical trial. “There were an uneven number of severely depressed patients in each group; with significantly fewer severely depressed people in the apparent ‘effective’ (25mg) dose group,” he says. “This does not appear to be acknowledged in the paper.”

Additionally, 179 of the 233 participants in the study reported adverse events such as headache, nausea, and dizziness, and a few experienced suicidal ideation or self-injury. These serious side effects are not uncommon in depression studies, but Kevin McConway, a professor emeritus of applied statistics at The Open University in the UK, who was not involved in the study, tells CNN, “Remember that this is in people who were assessed not to be at significant risk of suicide when they entered the trial. The numbers were fairly small, but this is something that will need to be taken carefully into account in any later-stage trials.” 

The drug is currently being tested in two Phase 3 trials, the results of which will be released at the end of 2024 at the earliest, Goodwin tells Reuters.



Source link

Previous Post

Crowdsourced cell phone data could keep bridges safe and strong

Next Post

What You Need to Know About Iran’s Surveillance Tech

Next Post

What You Need to Know About Iran's Surveillance Tech

Recommended

Humans Are Still Evolving Thanks to Microgenes

January 4, 2023

Drugs Hitch a Ride on Algae for Targeted Delivery | TS Digest

February 11, 2023

Don't miss it

Technology

Combining Climate Stressors Leads to Unique Changes in the Genome

March 21, 2023
Science News

By flying over atmospheric rivers, scientists aim to improve forecasts

March 20, 2023
Science News

Covid-19 threat expected to become on par with flu this year, says WHO

March 20, 2023
Science News

Early universe was full of stars 10,000 times the size of our sun

March 20, 2023
Technology

What High-Tech Prizes Does the Downed U.S. Drone Hold? Russia Really Wants to Know

March 20, 2023
Technology

Animal Personalities Can Trip Up Science, But There’s a Solution

March 20, 2023

© 2022 Science News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Science News
  • Technology
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • Science News
  • Technology
  • Contact us

© 2022 Science News Hubb All rights reserved.